Aura Biosciences, Inc. Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss
Aura Biosciences, Inc. (AURA) reported Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss of $632.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments · last filed 2026-08-11
- Aura Biosciences, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-06-30 was $340.00K, a 19.72% increase year-over-year.
- Aura Biosciences, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-03-31 was $292.00K, a 41.72% decline year-over-year.
- Aura Biosciences, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-12-31 was $424.00K, a 44.86% decline year-over-year.
- Aura Biosciences, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-09-30 was $337.00K, a 68.48% decline year-over-year.
- Aura Biosciences, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2025 was $1.55M, a 66.82% decline from fiscal 2024.
- Aura Biosciences, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was $4.66M, a 16.71% increase from fiscal 2023.
- Aura Biosciences, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was $3.99M, a 657.50% increase from fiscal 2022.
- Aura Biosciences, Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was $527.00K.
| Period end | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $340.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $632.00K 10-Q · filed 2026-08-11 | $1.06M derived: sum of 3 quarters · filed 2026-08-11 | $1.39M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $292.00K 10-Q · filed 2026-05-11 | $716.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.05M derived: sum of 3 quarters · filed 2026-05-11 | $1.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $424.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $761.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.04M derived: sum of 3 quarters · filed 2026-08-11 | $1.55M 10-K · filed 2026-03-30 |
| 2025-09-30 | $337.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $621.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.12M 10-Q · filed 2025-11-13 | $1.89M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $284.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $785.00K 10-Q · filed 2026-08-11 | $1.55M derived: sum of 3 quarters · filed 2026-08-11 | $2.62M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $501.00K 10-Q · filed 2026-05-11 | $1.27M derived: sum of 2 quarters · filed 2026-05-11 | $2.34M derived: sum of 3 quarters · filed 2026-05-11 | $3.65M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $769.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.84M derived: sum of 2 quarters · filed 2026-03-30 | $3.15M derived: sum of 3 quarters · filed 2026-03-30 | $4.66M 10-K · filed 2026-03-30 |
| 2024-09-30 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.38M derived: sum of 2 quarters · filed 2025-11-13 | $3.89M 10-Q · filed 2025-11-13 | $5.03M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $2.82M 10-Q · filed 2025-08-13 | $3.96M derived: sum of 3 quarters · filed 2025-08-13 | $4.78M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.51M 10-Q · filed 2025-05-15 | $2.65M derived: sum of 2 quarters · filed 2025-05-15 | $3.47M derived: sum of 3 quarters · filed 2025-05-15 | $4.49M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $1.96M derived: sum of 2 quarters · filed 2025-03-24 | $2.99M derived: sum of 3 quarters · filed 2025-03-24 | $3.99M 10-K · filed 2025-03-24 |
| 2023-09-30 | $821.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.85M derived: sum of 2 quarters · filed 2024-11-12 | $2.85M 10-Q · filed 2024-11-12 | $3.08M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.03M 10-Q · filed 2024-08-08 | $2.26M derived: sum of 3 quarters · filed 2024-08-08 | $2.42M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.00M 10-Q · filed 2024-05-09 | $1.23M derived: sum of 2 quarters · filed 2024-05-09 | $1.39M derived: sum of 3 quarters · filed 2024-05-09 | $1.53M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $228.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $384.00K derived: sum of 2 quarters · filed 2024-03-27 | $522.00K derived: sum of 3 quarters · filed 2024-03-27 | $527.00K 10-K · filed 2024-03-27 |
| 2022-09-30 | $156.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $294.00K derived: sum of 2 quarters · filed 2023-11-09 | $299.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $138.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $143.00K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $5.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |